Journal of Allergy and Clinical Immunology
Remibrutinib Provides Fast Symptom Relief in the Pooled REMIX-1/-2 Studies
Windom H, Machado P, Ortmann C, et al
This pooled analysis of two Phase 3 trials (REMIX-1/-2) evaluated the early, daily symptom control effects of remibrutinib versus placebo in patients with chronic spontaneous urticaria using daily Urticaria Activity Scores. Remibrutinib provided rapid symptom improvement, with reductions in disease activity observed within 12 hours and sustained through the first week of treatment. A substantially greater proportion of patients achieved low symptom severity compared with placebo, supporting its fast onset and effectiveness in CSU symptom control.
Previous Article
- • Attack Rate Reductions After Berotralstat Initiation Among Patients With Hereditary Angioedema
- • Navenibart Delays Time to First HAE Attack
- • APG777 in Patients With Atopic Dermatitis and Evidence of Type 2 Inflammatory Comorbidities
- • Skin Lipid Biomarkers for Prediction of Atopic Dermatitis and Food Allergy Risk
- • Fel d 1-Expressing Plant-Derived Bioparticle for CAT Allergy
- • Dietary Consumption Feasibility Following Treatment With Multi-Food Oral Immunotherapy or Omalizumab
- • Remibrutinib Provides Fast Symptom Relief in the Pooled REMIX-1/-2 Studies
- • Real-Time AI Identification and Quantification of Airborne Pollen Species
- • Artificial Intelligence vs Board-Certified Allergist/Immunologists: Responses to Food Allergy Questions
- • HLA-A*32:01 Carriage Is Associated With Lamotrigine-Induced Drug Reaction With Eosinophilia and Systemic Symptoms
- • Microbiome Associations With Food Sensitization in the ACTIVATE Trial
- • Exposure to Vaginal Microbiome in C-Section Infants at High Risk for Allergies
- • RAPIDe-3: Oral Deucrictibant Immediate-Release Capsule in Hereditary Angioedema
- • Oral Deucrictibant Improves Health-Related Quality of Life in Participants With Hereditary Angioedema
- • Hereditary Angioedema Attacks With Sebetralstat in the KONFIDENT-S Study
- • HAE Attack Reduction With BW-20805
- • Phase 1b/2 Trial of Navenibart for Hereditary Angioedema
- • Phase 2 Results: LP-003 Significantly Decreases Chronic Spontaneous Urticaria Disease Activity
- • Off-Treatment Efficacy of Barzolvolimab in Chronic Spontaneous Urticaria
- • Dose-Finding Study of Barzolvolimab in Patients With Chronic Spontaneous Urticaria
- • The Phase 2 APEX Study of APG777 in Atopic Dermatitis
- • The Gut–Skin Axis in Vietnamese Children With Atopic Dermatitis
- • STMC-103H Reduces Risk of Atopic Dermatitis and Food Allergy in At-Risk Infants
- • Biomarker Discovery for Food Allergy Using Artificial Intelligence
- • REGN1908-1909 Suppresses Cat-Allergen Induced Allergic Conjunctivitis and Skin Test Reactivity
- • The COMBINE Trial: Dupilumab Enhances Desensitization and Reduces GI Symptoms
- • Novel Technique for Measuring Fungal Function in Dust
- • Pet Sensitization Impacts on Asthma Exacerbations
- • Risk of Respiratory Tract Infections with Asthma Biologics
- • GLP-1 Receptor Agonists Reduce Asthma Exacerbations In Obese Type 2 Diabetics
